대한뉴팜

Daehan New Pharm’s export pharmaceutical product, Trimedat, which received the $10 million Export Tower award in 2015, was honored at the Russian Pharma Awards. This award ceremony is one of the most important events in the Russian pharmaceutical industry, with over 4,000 doctors voting directly to determine the winning medicines. The award signifies that Trimedat tablets are recognized as a reliable and excellent product in the Russian market.

This achievement was made possible through close collaboration with Russian partners over more than ten years. In 2015, Trimedat recorded sales of $2.3 million, with a target of $3.5 million for the current year. To increase exports to Russia, Daehan New Pharm is in the process of registering one injectable product, one antibiotic, and one oral medication. Upon completion of these three registrations, the company expects to achieve export sales of $10 million solely from the Russian market.

To sustain export growth, Daehan New Pharm is strategically focusing on Russia, China, and Southeast Asia as export bases, while also developing new markets in untapped regions such as Cuba, and expanding in growing markets like Pakistan, Azerbaijan, and Mongolia. Additionally, the company is concentrating its efforts on exporting veterinary pharmaceuticals to Middle Eastern markets.

Currently, Daehan New Pharm has established a worldwide network through strategic partnerships in over 20 countries and more than 60 alliances globally.